• Hatteras Venture Partners portfolio company CREATE Medicines secured Australian HREC clearance to start a first-in-human Phase 1/2 trial of CRT-402.
• Trial will evaluate CD19-targeted in vivo CAR-T candidate CRT-402 in autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies.
• Decision enables patient enrollment in Australia, marking CREATE’s first clinical program outside oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hatteras Venture Partners published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.